enGene Therapeutics Inc. share price logo

enGene Therapeutics Inc.

NASDAQ: ENGN

$1.79

+0.03

(+1.70%)

as on

enGene Therapeutics Inc. Stock Performance

as on August 1, 2026 at 2:16 pm IST

  • Day's Low

    $1.71
    $1.79
    downward going graph

    4.47%

    Downside

  • 52 Week's Low

    52 Week's High

    $1.40
    $12.25
    downward going graph

    21.79%

    Downside

    584.36%

    Upside

    downward going graph

enGene Therapeutics Inc. share price movements today

Previous Close
$1.76
Open
$1.76
Volume
585.2K
Day's Low - High
$1.71 - $1.79
52 Week Low - High
$1.40 - $12.25

enGene Therapeutics Inc. Historical Returns

1 Month Return
+ 1.7 %
3 Month Return
-75.31 %
1 Year Return
-53.26 %
3 Year Return
0 %
5 Year Return
0 %

enGene Therapeutics Inc. Stock Fundamentals & Key Indicators

Check enGene Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$117.9M

EPS (TTM)

-1.7271

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-131.9M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-52.59%

enGene Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of enGene Therapeutics Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
enGene Therapeutics Inc. image
enGene Therapeutics Inc.
BUY$117.9MNANA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$40.9B554.78%NA0.00%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$122.3B136.68%28.6635.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$76.0B32.72%16.9829.65%NA

Stock Returns calculator for enGene Therapeutics Inc. Stock including INR - Dollar returns

The enGene Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

enGene Therapeutics Inc. investment value today

Current value as on today

₹50,932

Returns

-₹49,068

(-49.07%)

Returns from enGene Therapeutics Inc. Stock

-₹53,264 (-53.26%)

Dollar Impact

₹4,195 (+4.2%)

Analyst Recommendation on enGene Therapeutics Inc. Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for enGene Therapeutics Inc.. Average target price of $3.29

enGene Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on enGene Therapeutics Inc..

What analysts predicted

45.59%UPSIDE

Target Price

$3.29

Current Price

$1.79

Analyzed by

11 Analysts

Target

$3.29

enGene Therapeutics Inc. target price $3.29, a slight upside of 45.59% compared to current price of $1.79. According to 11 analysts rating.

Indian Investors' Interest in enGene Therapeutics Inc. Stock

Search interest for enGene Therapeutics Inc. Stock has decreased by -62% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-62% versus previous 30 day period

enGene Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Apr 2024
Jul 2024
Oct 2024
Jan 2025
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Total Revenue
-
-
-
0
-
-
-
-
-
-
Gross Profit
-
0
0
0
0
0
0
0
0
0
Operating Income
-
-17
-16
-17
-26
-27
-29
-39
-31
31
EBITDA
-
-14
-13
-14
-23
-24
-27
-37
-28
-31
Interest Expense
-
0
0
0
0
0
0
0
0
0
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-
-14
-14
-15
-24
-25
-28
-38
-29
30
Income Tax Expense
-
0
0
0
0
0
0
0
-
-
Net Income
-14
-14
-14
-15
-24
-25
-28
-37
-29
30
Net Profit Margin
0.00%
0.00%
0.00%
-3187.29%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

enGene Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

Oct 2020
Dec 2020
Oct 2021
Dec 2021
Oct 2022
Dec 2022
Oct 2023
Dec 2023
Oct 2024
Oct 2025
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
0
-
0
0
Operating Income
-13
-
-15
-
-19
-
-26
-
-62
-123
EBITDA
-12
-
-18
-
-22
-
-94
-
-52
-113
Interest Expense
3
-
5
-
1
-
4
-
2
2
Depreciation
0
-
0
-
0
-
0
-
0
0
Income Before Tax
-15
-
-23
-
-24
-
-99
-
-55
-117
Income Tax Expense
4
-
4
-
0
-
0
-
0
-
Net Income
-15
-15
-23
-23
-24
-24
-99
-99
-55
-117
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

enGene Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

Apr 2024
Jul 2024
Oct 2024
Jan 2025
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Apr 2026
Net Income
-14
-14
-15
-24
-25
-28
-37
-29
-30
Operating Cash Flow
-14
-7
-19
-25
-22
-25
-24
-28
-30
Investing Cash Flow
0
0
-125
-84
17
1
40
-126
23
Financing Cash Flow
193
0
60
0
0
0
1
141
0
Change in Cash
179
-7
-84
-110
-4
-24
17
-13
-6

enGene Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

Oct 2021
Oct 2022
Oct 2023
Oct 2024
Oct 2025
Net Income
-23
-24
-99
-55
-117
Operating Cash Flow
-15
-17
-24
-48
-99
Investing Cash Flow
0
0
0
-125
-25
Financing Cash Flow
22
27
86
265
1
Change in Cash
6
9
61
91
-122

Global Institutional Holdings in enGene Therapeutics Inc.

Funds
Holdings
Millennium Management LLC
1.43%
VR Adviser, LLC
7.12%
Kennedy Capital Management Inc
0.64%
MPM Oncology Impact Management LP
2.75%
Kynam Capital Management, LP
2.03%
See all

enGene Therapeutics Inc. News & Key Events

  • img

    Today's Timeline - 11 November

    Tue, 09:07 PM

    -

    enGene reports promising Phase 2 trial data, leading to a 64.73% stock increase.

Insights on enGene Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 412.0% return, outperforming this stock by 465.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, ENGN stock has moved down by -75.3%

About enGene Therapeutics Inc.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
OrganisationenGene Therapeutics Inc.
Headquarters4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
IndustryBiotechnology
CEOMr. Ronald H. W. Cooper
E-voting on sharesClick here to vote

Key Management of enGene Therapeutics Inc.

Name

Title

Dr. Anthony T. Cheung Ph.D.

Co-Founder & Chief Scientific Officer

Ms. Joan Connolly

Chief Technology Officer

Ms. Jill Buck

Chief Development Officer

Ms. Amy Pott

Chief Global Commercialization Officer

Mr. Ronald H. W. Cooper

President, CEO & Director

Dr. William J. Grossman M.D., Ph.D.

Interim Chief Medical Officer & Director

Ms. Tara Place M.B.A.

Senior VP of Human Resources

Mr. Matthew Boyd

Chief Regulatory Officer

Ms. Kathleen Richton

VP & Controller

FAQs

What is enGene Therapeutics Inc. share price today?

enGene Therapeutics Inc. share price today is $1.79 as on at the close of the market. enGene Therapeutics Inc. share today touched a day high of $1.79 and a low of $1.71.

What is the 52 week high and 52 week low for enGene Therapeutics Inc. share?

enGene Therapeutics Inc. share touched a 52 week high of $12.25 on and a 52 week low of $1.40 on . enGene Therapeutics Inc. stock price today i.e. is closed at $1.79,which is 85.39% down from its 52 week high and 27.86% up from its 52 week low.

What is enGene Therapeutics Inc.'s market capitalisation today?

enGene Therapeutics Inc. market capitalisation is $0.00T as on .

How to invest in enGene Therapeutics Inc. Stock (ENGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for enGene Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in enGene Therapeutics Inc. Shares that will get you 0.8380 shares as per enGene Therapeutics Inc. share price of $1.79 per share as on August 1, 2026 at 8:46 am IST.

What is the minimum amount required to buy enGene Therapeutics Inc. Stock (ENGN) from India?

Indian investors can start investing in enGene Therapeutics Inc. (ENGN) shares with as little as ₹95.38 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.80 in enGene Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on enGene Therapeutics Inc. share’s latest price of $1.79 as on August 1, 2026 at 8:46 am IST, you will get 5.5866 shares of enGene Therapeutics Inc.. Learn more about fractional shares .